









Markets
/
Stocks
/
nasdaq-atai
/

ATAI Life Sciences NV

ATAI



View Detailed Chart

3.390USD

-0.150-4.23%

Market hours （ET）Quotes delayed by 15 min

517.27MMarket Cap

LossP/E TTM



ATAI Life Sciences NV

3.390

-0.150-4.23%

Overview Financials Analysis Company

Overview

Financials

Analysis

Company

Intraday

30m

Today

-4.23%

5 Days

-2.85%

1 Month

-6.60%

6 Months

-37.79%

Year to Date

-17.11%

1 Year

+130.64%

View Detailed Chart

TradingKey Stock Score of ATAI Life Sciences NV

Currency: USD Updated: 2026-03-27

Key Insights

ATAI Life Sciences NV's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 125 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.45.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ATAI Life Sciences NV's Score

Industry at a Glance

Industry Ranking

125 / 391

Overall Ranking

244 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

ATAI Life Sciences NV Highlights

StrengthsRisks

Atai Beckley NV, formerly ATAI Life Sciences NV, is a clinical-stage biopharmaceutical company. The Company focused on developing treatments for mental health disorders. The Company's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 1202.23% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 4.09M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 4.09M.

Overvalued

The company’s latest PE is -1.15, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 45.07M shares, increasing 0.04% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 17.41K shares of this stock.